Brain Genomics Superstruct Project

Massachusetts General Hospital1 site in 1 country61 target enrollmentApril 2011

ConditionsAutism Spectrum Disorders

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Autism Spectrum Disorders
Sponsor: Massachusetts General Hospital
Enrollment: 61
Locations: 1
Primary Endpoint: Neuroimaging phenotype
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to explore the effects of genes and genetic variation on brain structure and function. Investigators at Harvard plan to explore the relationship between candidate genes that affect cognitive performance and brain structure/function. Since brain phenotypes reflect more proximal sequelae of gene activity, neuroimaging measures may show greater sensitivity than cognitive performance to measure gene effects.

Registry

clinicaltrials.gov

Start Date

April 2011

End Date

January 2015

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Massachusetts General Hospital

Responsible Party

Principal Investigator

Gagan Joshi

Clinical Investigator, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

•13 years or older
•Subject must have a current DSM-IV diagnosis of high functioning ASD, based on past evaluations at the Bressler Clinic.
•Subjects must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
•Each subject must understand the nature of the study. The subject must sign an IRB approved informed consent.

Exclusion Criteria

•IQ \< 70 bassed on evaluation in the Bressler Clinic.
•Contraindication to MRI including presence of metal or surgical devices (plates, implants, braces or other items).
•Neuropsychiatric conditions (such as dementia) which sufficiently impair cognition such that a surrogate consent would be required.
•Neurological disorders associated with gross brain pathology (other than atrophy), e.g., stroke, tumors, or demyelinating diseases.